Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration
Targovax has entered into a research collaboration with Prof. Michael Uhlin at Karolinska Institutet to develop and characterize novel ONCOS delivery vectorsOslo, Norway, 1 February 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a two-year research collaboration with Prof. Michael Uhlin of the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Stockholm, Sweden, to develop and characterize novel ONCOS oncolytic viruses.